Sökning: id:"swepub:oai:gup.ub.gu.se/96758" >
Adverse prognostic ...
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
-
Viale, (författare)
-
Giobbie-Hurder, (författare)
-
Gusterson, (författare)
-
visa fler...
-
Maiorano, (författare)
-
Mastropasqua, (författare)
-
Sonzogni, (författare)
-
Mallon, (författare)
-
Colleoni, (författare)
-
Castiglione-Gertsch, (författare)
-
Regan, (författare)
-
Price, (författare)
-
Brown, (författare)
-
Golouh, (författare)
-
Crivellari, (författare)
-
- Karlsson, Per, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
Ohlschlegel, (författare)
-
Gelber, (författare)
-
Goldhirsch, (författare)
-
Coates, (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. - 1569-8041. ; 21:2, s. 245-254
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- BACKGROUND: Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. PATIENTS AND METHODS: Patients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin-eosin-stained slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years). RESULTS: PVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy. CONCLUSION: Adequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative disease, while PVI may identify patients who will benefit particularly from adjuvant therapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- breast cancer
- endocrine treatmnet
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Viale,
-
Giobbie-Hurder,
-
Gusterson,
-
Maiorano,
-
Mastropasqua,
-
Sonzogni,
-
visa fler...
-
Mallon,
-
Colleoni,
-
Castiglione-Gert ...
-
Regan,
-
Price,
-
Brown,
-
Golouh,
-
Crivellari,
-
Karlsson, Per, 1 ...
-
Ohlschlegel,
-
Gelber,
-
Goldhirsch,
-
Coates,
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of oncolo ...
- Av lärosätet
-
Göteborgs universitet